LLY · News · 20261001N

Product / Drug Pipeline Progress - Foundayo

ELI LILLY & Co · 2026-10-01 · Importance 59 · Surprise 82

Post-hoc ATTAIN-1 analyses linked Foundayo (orforglipron) 17.2 mg to a predicted 57% reduction in 10-year type 2 diabetes risk and an 18% reduction in predicted cardiovascular disease risk versus placebo. Separate reporting said Foundayo showed superior weight loss and A1C reduction compared with oral semaglutide, strengthening Lilly’s positioning in the oral GLP-1 market. The findings support potential long-term healthcare-cost savings and broader demand for oral obesity and diabetes treatments.

Key facts

• Eli Lilly presented new Foundayo data showing superior weight loss and A1C reduction compared to oral semaglutide. source
• Foundayo (orforglipron) 17.2 mg was associated with a predicted 57% reduction in risk of type 2 diabetes vs. placebo in post-hoc analyses of ATTAIN-1. source
• Foundayo (orforglipron) 17.2 mg was associated with a predicted 18% reduction in risk of cardiovascular disease vs. placebo in post-hoc analyses of ATTAIN-1. source
• The ATTAIN-1 post-hoc analyses reported Foundayo was associated with reductions in predicted 10-year risk of type 2 diabetes and cardiovascular disease in adults with obesity or overweight with a weight-related medical problem. source